BUSINESS● LOWSep 16 · Sep 16, 2026, 4:15 PM
Solid Biosciences wins new Outperform at RBC on DMD opportunity
Seeking Alpha Tech · global
Solid Biosciences received a new "Outperform" rating from RBC due to its Duchenne muscular dystrophy (DMD) opportunity. This indicates a positive outlook from financial analysts for the company's prospects.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS33m agoQ2 forecasts $888M-$892M 2026 revenue while raising adjusted EBITDA to $253M-$256MSeeking Alpha TechBUSINESS33m agoCarvana expects full-year 2026 adjusted EBITDA in the higher end of $2.7B-$3.0B range as it targets 3M units and 13.5% marginSeeking Alpha Tech